Some reviews have also considered PI3K/Akt/mTOR inhibitors as potential candidates for therapies targeting specific signalling pathways, immunomodulatory approaches, and autophagy in endometriosis (Hung et al., 2021; Samare-Najaf et al., 2023; Zhang et al., 2023b; Kobayashi et al., 2024). This evidence concerns the gene AKT1 and endometriosis.